Does Rallies show Form 4 insider transactions for GANX?

Yes. Rallies tracks GANX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GANX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GANX. It does not provide personalized investment advice.

GANX (Gain Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Gain Therapeutics, Inc. Common Stock (GANX) is a publicly traded Healthcare sector company. As of May 21, 2026, GANX trades at $1.67 with a market cap of $69.10M and a P/E ratio of -2.70. GANX moved +4.09% today. Year to date, GANX is -44.44%; over the trailing twelve months it is -13.61%. Its 52-week range spans $1.41 to $4.34. Analyst consensus is strong buy with an average price target of $7.20. Rallies surfaces GANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GANX stock inside the company?

Recent GANX insider activity includes Mack Gene bought 14.40K, Islam Khalid bought 50.00K, RICHMAN ERIC I bought 5.00K, RICHMAN ERIC I bought 12.00K, and Riley Jeffrey Scott bought 30.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GANX Key Metrics

Key financial metrics for GANX
Metric	Value
Price	$1.67
Market Cap	$69.10M
P/E Ratio	-2.70
EPS	$-0.61
Dividend Yield	0.00%
52-Week High	$4.34
52-Week Low	$1.41
Volume	17
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-20.16M
Gross Margin	0.00%

Recent GANX Insider Trades

Mack Gene bought 14.40K (~$14.54K) on Aug 9, 2024.
Islam Khalid bought 50.00K (~$49.94K) on Aug 9, 2024.
RICHMAN ERIC I bought 5.00K (~$6.15K) on Jul 1, 2024.
RICHMAN ERIC I bought 12.00K (~$14.52K) on Jul 1, 2024.
Riley Jeffrey Scott bought 30.00K (~$115.77K) on Mar 28, 2024.

Latest GANX News

Gain Therapeutics Shares Rise About 3% After Narrower Q1 Loss — May 11, 2026
Gain Therapeutics Q1 R&D and G&A Costs Rise by $0.5M; GT-02287 Shows 81% Biomarker Reduction — May 11, 2026
Gain Therapeutics to Present Parkinson’s Drug Data at May 22 GBA1 Meeting — Apr 24, 2026
Gain Therapeutics Reports Stable MDS-UPDRS, 81% CSF GluSph Drop and $20.8M Cash — Mar 26, 2026
Gain Therapeutics Sees Stable MDS-UPDRS Scores and 6.7-Point Improvement After 90-Day GT-02287 Dosing — Mar 18, 2026

GANX Analyst Consensus

5 analysts cover GANX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.20.

Common questions about GANX

Who is trading GANX stock inside the company?: Recent GANX insider activity includes Mack Gene bought 14.40K, Islam Khalid bought 50.00K, RICHMAN ERIC I bought 5.00K, RICHMAN ERIC I bought 12.00K, and Riley Jeffrey Scott bought 30.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GANX?: Yes. Rallies tracks GANX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GANX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GANX. It does not provide personalized investment advice.